ICU Medical (NASDAQ:ICUI) Price Target Increased to $203.00 by Analysts at Raymond James

ICU Medical (NASDAQ:ICUI) had its price target upped by research analysts at Raymond James from $185.00 to $203.00 in a report issued on Tuesday, The Fly reports. The firm currently has a “positive” rating on the medical instruments supplier’s stock. Raymond James’ price target points to a potential upside of 12.77% from the stock’s previous close.

ICUI has been the subject of a number of other research reports. Zacks Investment Research lowered shares of ICU Medical from a “hold” rating to a “sell” rating in a report on Wednesday, August 14th. TheStreet cut shares of ICU Medical from a “b-” rating to a “c+” rating in a research report on Monday, August 12th. ValuEngine raised shares of ICU Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, BidaskClub raised shares of ICU Medical from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. ICU Medical presently has a consensus rating of “Hold” and an average price target of $242.00.

ICUI traded up $1.35 during trading on Tuesday, reaching $180.02. 3,589 shares of the company’s stock were exchanged, compared to its average volume of 202,311. The company’s fifty day moving average price is $159.22 and its 200-day moving average price is $201.70. ICU Medical has a fifty-two week low of $148.89 and a fifty-two week high of $259.72. The firm has a market capitalization of $3.46 billion, a PE ratio of 23.30 and a beta of 0.91.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Monday, November 11th. The medical instruments supplier reported $1.65 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.03. ICU Medical had a net margin of 3.56% and a return on equity of 12.41%. The firm had revenue of $307.47 million during the quarter, compared to analyst estimates of $297.83 million. During the same quarter in the previous year, the business earned $1.85 EPS. The business’s quarterly revenue was down 6.0% compared to the same quarter last year. Equities research analysts forecast that ICU Medical will post 7.21 earnings per share for the current year.

In related news, VP Virginia Ruth Sanzone sold 3,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $154.08, for a total value of $462,240.00. Following the sale, the vice president now directly owns 55 shares of the company’s stock, valued at approximately $8,474.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert S. Swinney sold 373 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $153.49, for a total transaction of $57,251.77. Following the completion of the sale, the director now directly owns 18,845 shares in the company, valued at $2,892,519.05. The disclosure for this sale can be found here. Insiders sold a total of 5,451 shares of company stock worth $862,736 over the last ninety days. 11.40% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of ICUI. Price T Rowe Associates Inc. MD lifted its stake in shares of ICU Medical by 22.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,478,883 shares of the medical instruments supplier’s stock valued at $876,365,000 after buying an additional 640,425 shares in the last quarter. Findlay Park Partners LLP purchased a new stake in shares of ICU Medical during the second quarter worth about $75,573,000. Janus Henderson Group PLC grew its stake in shares of ICU Medical by 5.2% during the second quarter. Janus Henderson Group PLC now owns 2,825,836 shares of the medical instruments supplier’s stock worth $711,856,000 after acquiring an additional 140,123 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of ICU Medical by 41.5% during the second quarter. Wells Fargo & Company MN now owns 418,889 shares of the medical instruments supplier’s stock worth $105,522,000 after acquiring an additional 122,856 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of ICU Medical by 28.1% during the second quarter. Invesco Ltd. now owns 428,233 shares of the medical instruments supplier’s stock worth $107,876,000 after acquiring an additional 93,904 shares during the last quarter. 94.04% of the stock is currently owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Featured Story: What is the balance sheet?

The Fly

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.